Endothelin-1 accentuates the proatherosclerotic effects associated with C-reactive protein

Danny Ramzy1, Vivek Rao, Laura C Tumiati

  • 1Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada.

Insights

Endothelin-1 accentuates C-reactive protein's negative impact on nitric oxide production by inhibiting protein kinase C. This suggests targeting endothelin-1 and protein kinase C could improve vascular health and reduce atherosclerosis.

Area of Science:

  • Cardiovascular Biology
  • Inflammation Research
  • Endothelial Function

Background:

  • C-reactive protein (CRP) is a proinflammatory marker implicated in atherosclerosis development.
  • Endothelin-1 (ET-1) and nitric oxide (NO) homeostasis are vital for vascular health, regulating vasomotor function and endothelial surface properties.
  • CRP impairs endothelial NO production, a process potentially modulated by protein kinase C (PKC).

Purpose of the Study:

  • To investigate whether ET-1 exposure modifies CRP's effects on endothelial NO production.
  • To determine the role of PKC in the interaction between CRP and ET-1 on NO homeostasis.
  • To explore potential therapeutic targets for mitigating CRP-induced proatherosclerotic effects.

Main Methods:

  • Human endothelial cells were exposed to CRP, ET-1, or both, alongside a control.
  • Measurements included endothelial NO synthase (eNOS) expression, total NO production, and PKC translocation and activity.
  • Specific PKC isoforms, such as PKC lambda, were assessed.

Main Results:

  • Both CRP and ET-1 individually reduced eNOS expression and NO production.
  • Coincubation synergistically reduced NO production by 70% compared to control.
  • CRP and ET-1 synergistically inhibited PKC lambda translocation and activity, with CRP alone also reducing PKC activity.

Conclusions:

  • ET-1 exacerbates CRP-induced impairment of endothelial NO production through synergistic inhibition of PKC lambda.
  • Targeting ET-1 and stimulating PKC may offer a novel therapeutic approach to restore vascular NO homeostasis.
  • These findings highlight a potential strategy to counteract the proatherosclerotic actions of CRP.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...